Sanofi’s OX40-ligand Blocker Produces High Durable Response Rates in AD With Quarterly Dosing
Sanofi’s investigational OX40-ligand blocker amlitelimab produces sustained improvement in the signs and symptoms of atopic dermatitis (AD) in adults who previously responded and continued treatment and sustained off-drug improvements in those who stopped treatment. These are the main findings from part 2 of a phase 2b trial that was presented at the 2024 annual meeting […]